WINT — Windtree Therapeutics Cashflow Statement
0.000.00%
- $3.64m
- $2.52m
Annual cashflow statement for Windtree Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -32.6 | -67.6 | -39.2 | -20.3 | -1.79 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 8.41 | 53.8 | 22.4 | 4.75 | -14.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.33 | -0.058 | -1.78 | 2.02 | 1.37 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -25.3 | -23.7 | -19.5 | -13.4 | -15.4 |
Capital Expenditures | -0.291 | -0.279 | -0.013 | -0.015 | -0.012 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | — | 0.21 | 0 | — |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Cash from Investing Activities | -0.291 | -0.279 | 0.197 | -0.015 | -0.012 |
Financing Cash Flow Items | 2.8 | 1 | 0 | — | -0.268 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 20 | 29.4 | 3.08 | 11.6 | 12.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -5.65 | 5.42 | -16.2 | -1.86 | -2.68 |